Advertisement

Capacity Building for Health Technology Assessment in Jordan: Institutionalization and Its Use in Pricing and Reimbursement Decisions

Published:September 05, 2022DOI:https://doi.org/10.1016/j.vhri.2022.07.006

      Highlights

      • University-based education and professional training in health economics and pharmaceutical policy are helping to create a receptive environment, expertise, and local tools across many settings in Jordan.
      • Two distinct national health institutions embedded health technology assessment (HTA) into their reimbursement decisions: King Hussein Cancer Center and the Jordanian Royal Medical Services. Nevertheless, reimbursement decision-making processes vary across public health institutions, influencing the way in which HTA is implemented and used.
      • The existence of the National HTA Committee is a focal factor to accelerate the institutionalization of HTA at the national level in Jordan. Nevertheless, there is considerable resistance from various public health institutions to collaborate on data collection or sharing due to a lack of experts and time resources. Building capacity for HTA and experience sharing is a priority for further establishment of a national HTA work plan.

      Abstract

      Objectives

      This study aimed to describe the process of the institutionalization of health technology assessment (HTA) in Jordan. In particular, this study presents local policy perspectives on capacity building for HTA and the progress made toward its use in pricing and reimbursement decisions.

      HTA capacity building

      University-based education and professional development training in pharmacoeconomics and pharmaceutical policy have been the starting points to create a receptive environment, necessary expertise, and local tools across many settings in Jordan. International collaboration with HTA supporting bodies helped to build connections and informed policy development on local levels through projects, meetings, and discussions.

      HTA institutionalization and its use in pricing and reimbursement decisions

      Institutionalizing HTA in the King Hussein Cancer Center and the Royal Medical Services was the driving factor for HTA implementation and practice advancement; nevertheless, process transparency and experience sharing through reports and publications are still limited. The Jordan Food and Drug Administration’s pricing and formulary decisions require pharmacoeconomic consultation in selected cases according to the Jordanian Drug Law. Nevertheless, there is a lack of local methodological guidelines for conducting HTA. In addition, HTA practitioners and the regulatory scope of future HTA activities in Jordan cannot be determined yet.

      Recommendations and future directions

      Over the past 2 decades, Jordan has crossed a number of milestones and advanced further to implement HTA as a tool for evaluating health interventions. As a next step, legislation is needed to mandate the use of HTA and to enhance transparency in decision-making processes.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Value in Health Regional Issues
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kaló Z.
        • Bodrogi J.
        • Boncz I.
        • et al.
        Capacity building for HTA implementation in middle-income countries: the case of Hungary.
        Value Health. 2013; 2: 264-266
      1. Global spending on health: a world in transition. World Health Organization.
      2. Strengthening health financing systems in the eastern Mediterranean region towards universal health coverage: health financing atlas 2018. World Health Organization.
        https://apps.who.int/iris/handle/10665/311328
        Date accessed: August 15, 2021
        • Balkhi B.
        • Alshayban D.
        • Alotaibi N.M.
        Impact of healthcare expenditures on healthcare outcomes in the Middle East and North Africa (MENA) region: a cross-country comparison, 1995-2015.
        Front Public Health. 2020; 8624962
        • Nazer L.H.
        • Tuffaha H.
        Health care and pharmacy practice in Jordan.
        Can J Hosp Pharm. 2017; 70: 150-155
        • Almomani E.
        • Alabbadi I.
        • Fasseeh A.
        • et al.
        Implementation road map of health technology assessment in middle-income countries: the case of Jordan.
        Value Health Reg Issues. 2021; 25: 126-134
        • Brosk H.
        • El-Samen T.A.
        • Saif J.A.
        • et al.
        Jordan national health accounts. USAID.
      3. The influence of health technology assessment. INAHTA.
        • Fasseeh A.
        • Karam R.
        • Jameleddine M.
        • et al.
        Implementation of health technology assessment in the Middle East and North Africa: comparison between the current and preferred status.
        Front Pharmacol. 2020; 11: 15
        • Alefan Q.
        • Hamdouni E.
        • Alhamad H.
        • Mukattash T.
        • Rascati K.
        Barriers to implementing pharmacoeconomics: interview study.
        Expert Rev Pharmacoecon Outcomes Res. 2021; 21: 93-104
        • Kaló Z.
        • Gheorghe A.
        • Huic M.
        • Csanádi M.
        • Kristensen F.
        HTA implementation roadmap in Central and Eastern European Countries.
        Health Econ. 2016; 25: 179-192
        • Pichler F.
        • Oortwijn W.
        • Ruether A.
        • Trowman R.
        Defining capacity building in the context of HTA: a proposal by the HTAi Scientific Development and Capacity Building Committee.
        Int J Technol Assess Health Care. 2019; 35: 362-366
        • Chalkidou K.
        • Lord J.
        • Obeidat N.
        • et al.
        Piloting the development of a cost-effective evidence-informed clinical pathway: managing hypertension in Jordanian primary care.
        Int J Technol Assess Health Care. 2011; 27: 151-158
        • Alabbadi I.
        • Almomani E.
        • Alshazili M.
        Drug selection for formulary inclusion: an exploratory case study of oncology medicines in Jordan.
        Value Health Reg Issues. 2020; 21: 211-221
        • Hammad E.
        • Mousa R.
        • Hammad A.
        • Al-Qudah M.
        Awareness, knowledge, and attitudes of health professions students toward health economics and pharmacoeconomics education in Jordan.
        Curr Pharm Teach Learn. 2020; 12: 1072-1080
        • Alefan Q.
        • AlImam S.
        • Mukattash T.
        • Mhaidat N.
        • Alabbadi I.
        • Rascati K.
        Pharmacoeconomics education in WHO eastern Mediterranean region.
        Curr Pharm Teach Learn. 2015; 7: 819-825
      4. Jordan Food and Drug Administration. In:2021. Accessed August 29, 2022. http://www.jfda.jo/.

        • Hammad E.
        The use of economic evidence to inform drug pricing decisions in Jordan.
        Value Health. 2016; 19: 233-238
        • Alabbadi I.
        Cost impact of purchasing pharmaceuticals jointly in the public health sector in Jordan.
        Jordan J Pharm Sci. 2011; 4: 97-104
        • Abbott R.
        • Bader R.
        • Bajjali L.
        • et al.
        The price of medicines in Jordan: the cost of trade-based intellectual property.
        J Generic Med. 2012; 9: 75-85
        • Alefan Q.
        • Amairi R.
        • Tawalbeh S.
        Availability, prices and affordability of selected essential medicines in Jordan: a national survey.
        BMC Health Serv Res. 2018; 18: 787
        • Lafi R.
        • Robinson S.
        • Williams I.
        Economic evaluation and the Jordan rational drug list: an exploratory study of national-level priority setting.
        Value Health. 2012; 15: 771-776
      5. Health economics Diectorate. In:2021. [Online]. Accessed August 29, 2022. https://www.moh.gov.jo/Pages/viewpage.aspx?pageID=281.

        • Kaló Z.
        • Albbadi I.
        • Al Ahdab O.G.
        • et al.
        Implications of external price referencing of pharmaceuticals in Middle East countries.
        Expert Rev Pharmacoecon Outcomes Res. 2015; 15: 993-998
        • Al-Rabayah A.
        • Jaddoua S.
        Establishment and implementation of hospital-based health technology assessment at King Hussein Cancer Center: can our model be an example?.
        Int J Technol Assess Health Care. 2021; 37: e55
        • Löblová O.
        What has health technology assessment ever done for us?.
        J Health Serv Res Policy. 2018; 23: 134-136